At SpineX we are pushing the boundaries of research to find the most effective solutions for  patients with neurological conditions.

Our world-leading team can execute swiftly and effectively, bringing ideas from the bench to market with minimal delays. Our team has decades of cumulative MedTech experience, dozens of products brought to market, deep IP knowledge, and significant clinical evidence.

Our SCiP™ device has received FDA Breakthrough Device Designation for the treatment of movement disorders in cerebral palsy. We anticipate a multicenter pivotal trial to commence in H1 2024.

Our SCONE™ device has  received FDA Breakthrough Device Designation for the treatment of neurogenic  bladder due to spinal cord injury, multiple sclerosis, and stroke. Our pivotal clinical trial is currently ongoing at multiple centers across the US and globally.

To date we’ve raised

In Equity Financing
$ 0 M
In Nondilutive Funding
$ 0.2 M

With an estimated > $15B combined marketsize.
We are quick to market and have first-mover advantage.

Our mission

We aim to enhance, improve and restore quality of life for individuals living with neurological conditions through non-invasive neuromodulation solutions.

If you’re interested in helping us meet this unmet clinical
need, we’d love to talk to you.

To top